KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Operating Expenses (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Other Operating Expenses for 6 consecutive years, with -$185.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 1.15% year-over-year to -$185.8 million, compared with a TTM value of -$84.4 million through Dec 2025, up 40.01%, and an annual FY2025 reading of -$84.4 million, up 40.01% over the prior year.
  • Other Operating Expenses was -$185.8 million for Q4 2025 at Esperion Therapeutics, down from $41.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $41.3 million in Q3 2025 and bottomed at -$185.8 million in Q4 2025.
  • Average Other Operating Expenses over 5 years is -$7.0 million, with a median of $8.2 million recorded in 2022.
  • The sharpest move saw Other Operating Expenses skyrocketed 5654.84% in 2021, then crashed 1703.91% in 2024.
  • Year by year, Other Operating Expenses stood at $5.1 million in 2021, then decreased by 18.03% to $4.2 million in 2022, then skyrocketed by 175.29% to $11.5 million in 2023, then plummeted by 1703.91% to -$183.7 million in 2024, then fell by 1.15% to -$185.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for ESPR at -$185.8 million in Q4 2025, $41.3 million in Q3 2025, and $28.5 million in Q2 2025.